HK Stock Market Move | LAEKNA-B (02105) surged over 7% in late trading. The first subject enrollment has been completed in Phase I clinical trial of LAE118. The maximum amount of the licensing agreement is $527 million.

LAEKNA-B (02105) rose over 7% in the closing hours. As of the time of this report, it is up 6.26%, trading at HKD 6.955, with a transaction volume of HKD 10.8309 million. In terms of news, Lakkai Pharmaceuticals recently announced that the recruitment of subjects for its self-developed LAE118, aimed at advanced solid tumors, is underway in China, with the first patient successfully enrolled. This clinical study primarily assesses the safety, tolerability, pharmacokinetics, and preliminary efficacy of LAE118 as a monotherapy and in combination therapy. It is reported that LAE118 has received clinical trial application approvals in both China and the United States and has entered the Phase I clinical research stage. Public information shows that in June of this year, Lakkai Pharmaceuticals licensed the global rights for LAE118 outside of Greater China to Vasque Bio. The terms of the deal include a non-refundable upfront payment of USD 10 million, up to USD 517 million in milestone payments for development and sales, a tiered profit-sharing structure ranging from single to double digits, and a high double-digit percentage equity interest in Vasque Bio. Should Vasque Bio reach strategic cooperation or an acquisition regarding LAE118 in the future, Lakkai Pharmaceuticals retains the right to receive an additional share of the transaction value of up to 50%.